



## https://helda.helsinki.fi

Associations between Physical Exercise, Quality of Life, Psychological Symptoms and Treatment Side Effects in Early Breast Cancer

Vehmanen, Leena

2022-11-19

Vehmanen , L , Mattson , J , Karademas , E , Oliveira-Maia , A J , Sousa , B , Pat-Horenczyk , R , Mazzocco , K , Simos , P , Cardoso , F , Pettini , G , Marzorati , C , Kolokotroni , E ,
Stamatakos , G , Frasquilho , D & Poikonen-Saksela , P 2022 , 'Associations between
Physical Exercise, Quality of Life, Psychological Symptoms and Treatment Side Effects in
Early Breast Cancer ', Breast Journal , vol. 2022 , 9921575 . https://doi.org/10.1155/2022/9921575

http://hdl.handle.net/10138/352335 https://doi.org/10.1155/2022/9921575

cc\_by publishedVersion

Downloaded from Helda, University of Helsinki institutional repository.

This is an electronic reprint of the original article.

This reprint may differ from the original in pagination and typographic detail.

Please cite the original version.



**Research** Article

# Associations between Physical Exercise, Quality of Life, Psychological Symptoms and Treatment Side Effects in Early Breast Cancer

Leena Vehmanen (D, <sup>1</sup> Johanna Mattson (D, <sup>1</sup> Evangelos Karademas (D, <sup>2,3</sup> Albino J. Oliveira-Maia (D, <sup>4,5</sup> Berta Sousa (D, <sup>6</sup> Ruth Pat-Horenczyk (D, <sup>7</sup> Ketti Mazzocco (D, <sup>8,9</sup> Panagiotis Simos (D, <sup>3,10</sup> Fátima Cardoso (D, <sup>6</sup> Greta Pettini (D, <sup>8</sup> Chiara Marzorati (D, <sup>8</sup> Eleni Kolokotroni (D, <sup>11</sup> Georgios Stamatakos (D, <sup>11</sup> Diana Frasquilho (D, <sup>6</sup> and Paula Poikonen-Saksela (D<sup>1</sup>

<sup>1</sup>Helsinki University Hospital Comprehensive Cancer Center and University of Helsinki, Helsinki, Finland

<sup>2</sup>Department of Psychology, University of Crete, Rethymno, Greece

<sup>3</sup>Foundation for Research and Technology-Hellas, Institute of Computer Science, Heraklion, Greece

<sup>4</sup>Champalimaud Research & Clinical Centre, Champalimaud Foundation, Lisboa, Portugal

<sup>5</sup>NOVA Medical School NMS, Universidade Nova de Lisboa, Lisboa, Portugal

<sup>6</sup>Breast Unit, Champalimaud Clinical Centre/Champalimaud Foundation, Lisboa, Portugal

<sup>7</sup>School of Social Work and Social Welfare, The Hebrew University of Jerusalem, Jerusalem, Israel

<sup>8</sup>Applied Research Division for Cognitive and Psychological Science, European Institute of Oncology IRCCS, Milan, Italy

<sup>9</sup>Department of Oncology and Hemato-oncology, University of Milan, Milan, Italy

<sup>10</sup>School of Medicine, University of Crete, Rethymno, Greece

<sup>11</sup>In Silico Oncology and In Silico Medicine Group, Institute of Communication and Computer Systems,

School of Electrical and Computer Engineering, National Technical University of Athens, Athens, Greece

Correspondence should be addressed to Paula Poikonen-Saksela; paula.poikonen-saksela@hus.fi

Received 28 April 2022; Revised 29 October 2022; Accepted 1 November 2022; Published 19 November 2022

Academic Editor: Pranshu Sahgal

Copyright © 2022 Leena Vehmanen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Identifying and understanding modifiable factors for the well-being of cancer patients is critical in survivorship research. We studied variables associated with the exercise habits of breast cancer patients and investigated if the achievement of exercise recommendations was associated with enhanced quality of life and/or psychological well-being. Material and Methods. 311 women from Finland, Portugal, Israel, and Italy receiving adjuvant therapy for stage I-III breast cancer answered questions about sociodemographic factors and physical exercise. Quality of life was assessed by the EORTC C30 and BR23 questionnaires. Anxiety and depression were evaluated using the HADS scale. Results. At the beginning of adjuvant therapy and after twelve months, 32% and 26% of participants were physically inactive, 27% and 30% exercised between 30 and 150 minutes per week, while 41% and 45% exercised the recommended 150 minutes or more per week. Relative to other countries, Finnish participants were more likely to be active at baseline and at twelve months (89% vs. 50%, p < 0.001 and 87% vs. 64%, p < 0.001). Participants with stage I cancer were more likely to be active at twelve months than those with a higher stage (80% vs. 70%, p < 0.05). The inactive participants reported more anxiety (p < 0.05) and depression (p < 0.001), lower global quality of life (p < 0.001), and more side effects (p < 0.05) than the others at twelve months. Accordingly, those who remained inactive or decreased their level of exercise from baseline to twelve months reported more anxiety (p < 0.01) and depression (p < 0.001), lower global quality of life (p < 0.001), and more side effects (p < 0.05) than those with the same or increased level of exercise. *Conclusion*. For women with early breast cancer, exercise was associated with a better quality of life, less depression and anxiety, and fewer adverse events of adjuvant therapy. Trial registration number: NCT05095675. Paula Poikonen-Saksela on behalf of Bounce consortium (https:// www.bounce-project.eu/).

## 1. Introduction

Breast cancer is the most common malignancy in women and its' prognosis is generally excellent [1]. To facilitate offering interventions and education to promote quality of life and mental health in survivors, it is important to recognize the modifiable factors related to the well-being of these patients. Physical inactivity is a known risk factor for breast cancer [2] and many observational studies suggest an inverse association between physical activity and exercise after breast cancer diagnosis and breast cancer and/or all-cause mortality [3-7]. Exercise interventions [8-15] or physical activity in general [16] have resulted in positive effects on the well-being of breast cancer patients. Small-to-moderate benefits of exercise have been noted concerning the quality of life, physical fitness [8, 11, 12], fatigue [11, 12, 17], and depression [11, 18].

In 2010, the American College of Sports Medicine convened a roundtable to explore the literature on the safety and efficacy of physical exercise both during and after adjuvant cancer therapy and to provide guidelines on appropriate exercise [19]. It was concluded that exercise training is safe both during and after cancer therapies and improves physical functioning, quality of life, and cancerrelated fatigue in cancer survivors [19]. The scale of these benefits to physical functioning and quality of life has led to recommending cancer survivors to follow the 2008 US Department of Health and Human Services (US DHHS) Physical Activity Guidelines for Americans [19]. The US DHHS guidelines state that patients with chronic conditions such as cancer should be as physically active as their abilities and conditions allow [20]. Recommended periods of aerobic activity are 150 minutes of moderate-intensity exercise or 75 minutes of vigorous exercise a week. Strength training was recommended 2-3 times per week, along with stretching after each exercise session [19]. These recommendations are in line with the World Health Organization's recommendations on physical activity and sedentary behavior that were updated in 2020 [21]. However, a recent prospective cohort study of US cancer survivors (60% female) showed that physical inactivity is still highly prevalent as only 28% of the survivors reported the recommended 150 minutes or more of leisure time physical activity per week. Moreover, especially a combination of lack of physical activity and prolonged sitting was associated with heightened risks of all-cause and cancer mortality [22].

In this study, we described the exercise habits of early breast cancer patients during the first year from the start of oncological treatments and explored sociodemographic and cancer-related variables that are associated with such factors. Furthermore, we studied whether exercise according to current recommendations had an association with the quality of life or mental well-being of the patients one year after the start of adjuvant therapy.

#### 2. Materials and Methods

The BOUNCE project (European Union's Horizon 2020 Research and Innovation Programme under grant agreement No 777167) studies the resilience of early breast cancer patients. Between 2019 and 2020, 816 participants from Finland, Portugal, Israel, and Italy were recruited and gave their consent to be involved in the BOUNCE project. According to the WHO statistics (https://gco.iarc.fr/today/), all the participating countries belong to the category with the highest age-standardized breast cancer incidence worldwide.

Of the 816 participants, 555 were retained in the study after one year. To examine the relationships between aerobic exercise and quality of life and psychological symptoms, we used the data of 311 participants who had completed all the relevant questionnaires at study entry and after one year. Participants with incomplete data were more likely to have less years of education, and to have received chemotherapy or radiotherapy in comparison to those who provided complete data on all variables of interest at baseline and one year later (p < 0.01). No other differences in sociodemographic or medical variables between participants with complete and incomplete data were found. The study protocol was approved by the ethics committee of each participating institution and was conducted in accordance with the Declaration of Helsinki. Participants were screened from hospital records, received oral and written information about the study, and provided written informed consent.

2.1. Participants. The population of this substudy comprised women aged 40–70 years who were recently diagnosed with histologically confirmed stage I-III breast cancer and received either adjuvant or neo-adjuvant therapy in addition to surgery. Patients received chemotherapy, endocrine therapy, and/or anti-HER2 therapy according to the biological profile of their breast cancer, and radiotherapy according to local guidelines. Patients were eligible if they did not have a history of early onset mental disorder, other serious concomitant diseases diagnosed within the last 12 months, major surgery for severe disease, trauma within 4 weeks prior to study entry, or lack of complete recovery from the effects of surgery or other malignancy within the last five years.

2.2. Instruments. We collected participant data regarding sociodemographic factors, lifestyle, and psychological wellbeing using questionnaires via the online Noona tool or paper. Noona is an electronic patient-reported outcome (ePRO) software for patients with cancer. A trial assistant collected medical information from hospital records. In the BOUNCE project, data was collected from the participants every three months for up to 18 months. In the current substudy, we used data from the baseline and 12 months (M12) after beginning adjuvant therapy. The participants reported the time, in minutes, spent in aerobic moderate-intensity exercise such as walking, and in vigorous exercise such as running. In accordance with the US DHHS guidelines and for the purpose of our analyses, vigorous exercise was converted to moderate exercise so that one minute of vigorous exercise corresponded to two minutes of moderate exercise. In accordance with a recent British exercise survey (Active Lives Adult Survey May 2020/ 21 Report, https://sportengland.org/), the patients' physical activity was categorized into three levels: "inactive," if the amount of exercise was less than 30 minutes a week; "fairly active," if the amount of weekly exercise ranged from 30 to 149 minutes and "active," if the amount of weekly exercise was 150 minutes or more.

QOL and adverse effects were measured by the EORTC QLQ-C30 [23] with the breast cancer module supplement BR-23 [24]. The Global health/QOL scale describes patients' subjective quality of life and is based on two questions about physical condition and overall QOL. The Hospital Anxiety and Depression Scale HADS [25] was used to assess the psychological symptoms. Patients with a severe anxiety HADS score of 13 or more at baseline were offered psychological support according to the participating hospital's local practice.

2.3. Analyses. To examine the relationships between the level of exercise and sociodemographic and medical factors, we used a series of chi-square tests and ANOVAs. Also, a series of MANOVAs were used to examine the association between the level of exercise at baseline and at one year (M12), as well as the potential change in the level of exercise from baseline to M12 (as the independent variables), and the indices of psychological health and quality of life (i.e., symptoms of anxiety, depression, global quality of life, side effects, arm and breast symptoms; as the dependent variables). These analyses were performed after controlling for several sociodemographic and medical variables. Specifically, we controlled for the country of origin; age; education level (0-9 vs. > 9 years of education); marital status (married/ living with a partner vs. single/widowed); employment (employed vs. nonemployed/retired); income (very low/low vs. average/high), as reported by the participants, and after adjusting to the GDP income level of each country; tumor grade; tumor stage (I vs. II and III); therapy type (i.e., lumpectomy vs. mastectomy, radiotherapy, endocrine therapy, chemotherapy, and HER2-directed therapy) coded as a series of dummy variables; body mass index (BMI); receiving vs. not receiving psychotropic medication; receiving vs. not receiving formal psychological support/ counselling.

Tests of multicollinearity and multivariate normality (by determining the Mahalanobis distance from the available data and calculating the relevant chi-square values) were performed. Seven outliers were identified, which were excluded from the final sample (i.e., not included in the final sample of 311 participants). A post hoc examination revealed a statistical power of over .90 at an alpha level equal to 5% and a medium effect size, for the analyses performed. The

level of statistical significance was defined at p < 0.05. The Bonferroni correction for multiple comparisons was used whenever relevant.

#### 3. Results

3.1. Type of Exercise, Sociodemographic, and Medical Factors. Patient characteristics are presented in Table 1. At baseline, 32% of the participants were inactive (i.e., exercised less than 30 min per week), 27% were fairly active (i.e., exercised 31-149 min per week), and 41% were active (i.e., exercised 150 min or more per week). Twelve months later (M12), 26% of the participants reported being inactive, 30% fairly active, and 45% active. In addition, 36% reported that they stayed inactive or decreased their level of exercise from baseline to M12, whereas 64% reported that they maintained or increased their level of exercise. Of the "inactive" participants at baseline, almost half (49%) exercised more at M12; of the "fairly active" participants at baseline, 22% decreased and 37% increased their level of exercise; of the "active" participants, 34% decreased and 66% maintained their level of exercise. Overall, it was more likely for the participants to maintain or increase their level of exercise than to remain inactive or decrease their level of exercise [64% vs. 36%;  $\chi^2$  (4) = 69.97, p < 0.001].

Regarding the country of origin and sociodemographic variables (see also Table 2), participants from Finland were more likely to be fairly active or active at baseline (89% vs. 50% on average for all other countries;  $\chi^2$  (6) = 67.51, p < 0.001). No statistically significant differences existed across education level, marital status, income, tumor stage or grade, type of treatment, and receiving (vs. not receiving) any type of psychotropic medication or formal psychological support at baseline or at M12 ( $\chi^2$ s < 5.76, p > 0.05), as well as BMI and age, (*Fs*(2) < 1.90, p > 0.05).

Also at M12, participants from Finland were more likely to be fairly active or active (87% vs. 64% on average for all other countries;  $\chi^2$  (6) = 24.50, p < 0.001). Participants with stage I tumor (vs. stage II or III) were more likely to be fairly active or active at M12 (80% vs. 70%;  $\chi^2$  (2) = 6.39, p < 0.05). There were no other significant differences regarding all other sociodemographic or medical factors ( $\chi^2 s < 6.00$ , p > 0.05), age or BMI, (Fs(2) < 2.30, p > 0.05). Exercise habits at M12 according to sociodemographic and medical variables are presented in Table 2.

Finally, when comparing the change of exercise habits from baseline to M12, the likelihood to maintain or increase the level of exercise was higher in participants from Finland (72% vs. 57% on average for all other countries), with an average or high income (69% vs. 52% for low income), grade I tumor (76% vs. 61% for higher grades), and who were not undergoing chemotherapy (72% vs. 57% for those treated with chemotherapy;  $\chi^2$ s > 5.90, p < 0.05). Also, participants who maintained or increased their level of exercise were older (M = 55.34, SD = 0.63 years) than those who were inactive or decreased their level of exercise (M = 52.96, SD = 0.84 years; F(1) < 5.13, p > 0.05).

TABLE 1: Patient characteristics n = 311.

Age, years       55.41 (SD = 7.99)       40-70         BMI, kg/m <sup>2</sup> 26.05 (SD = 4.45)       17.26-40.89         ECOG       % at baseline       % at M12         0       90.8%       71.1%         1       8.9%       24%         2       0.3%       4.6%         3       —       0.3%         Country       N       %         Finland       143       46%         Portugal       76       24.4%         Israel       53       17%         Italy       39       12.5%         Education       —       0-9 years       14       4.5%         > 9 years       297       95.5%       Marital status       —         Married/living with a partner       272       87.5%         Single/widowed       39       12.5%         Working       =       =       =         Employed       230       74%         Nonemployed/retired       81       26%         Income       =       =         Very low/low       74       23.8%         Average/high       237       76.2%         Tumor grade       =       =	Variable	Mean	Range
BMI, kg/m²       26.05 (SD = 4.45)       17.26-40.89         ECOG       % at baseline       % at M12         0       90.8%       71.1%         1       8.9%       24%         2       0.3%       4.6%         3       -       0.3%         Country       N       %         Finland       143       46%         Portugal       76       24.4%         Israel       53       17%         Italy       39       12.5%         Education       -       -         0-9 years       14       4.5%         >9 years       297       95.5%         Marital status       -       -         Marital status       -       -         Marital status       -       -         Working       -       -       -         Employed       230       74%       Nonemployed/retired       81       26%         Income       -       -       -       -       -         Very low/low       74       23.8%       -       -       -         Ital       53       17%       -       -       -       -	Age, years	55.41 (SD = 7.99)	40-70
ECOG       % at baseline       % at M12         0       90.8%       71.1%         1       8.9%       24%         2       0.3%       4.6%         3       -       0.3%         Country       N       %         Portugal       143       46%         Portugal       76       24.4%         Israel       53       17%         Italy       39       12.5%         Education       -       -         0-9 years       14       4.5%         >9 years       297       95.5%         Marited/living with a partner       272       87.5%         Single/widowed       39       12.5%         Working       -       -         Employed       230       74%         Nonemployed/retired       81       26%         Income       -       -         Very low/low       74       23.8%         Average/high       237       76.2%         Tumor grade       -       -         I       152       48.9%         III       136       43.7%         III       136       43.7%	$BMI, kg/m^2$	26.05 (SD = 4.45)	17.26-40.89
0         90.8%         71.1%           1         8.9%         24%           2         0.3%         4.6%           3         -         0.3%           Country         N         %           Finland         143         46%           Portugal         76         24.4%           Israel         53         17%           Italy         39         12.5%           Education         -         -9 years         14         4.5%           >9 years         297         95.5%         Single/widowed         39         12.5%           Working         -         -         -         87.5%         Single/widowed         39         12.5%           Working         -         -         -         87.5%         Single/widowed         39         12.5%           Working         -         -         230         74%         Nonemployed/retired         81         26%           Income         -         -         237         76.2%         Tiumor grade         -         1         17         47.3%           II         152         48.9%         11%         136         43.7%         11%	ECOG	% at baseline	% at M12
1       8.9%       24%         2       0.3%       4.6%         3       -       0.3%         Country       N       %         Finland       143       46%         Portugal       76       24.4%         Israel       53       17%         Italy       39       12.5%         Education	0	90.8%	71.1%
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	1	8.9%	24%
3       - $0.3\%$ Country       N       %         Finland       143       46%         Portugal       76       24.4%         Israel       53       17%         Italy       39       12.5%         Education       - $0^{-9}$ years       14       4.5%         >9 years       297       95.5%         Marital status       -       Working         Married/living with a partner       272       87.5%         Single/widowed       39       12.5%         Working       -       -       -         Employed/retired       81       26%         Income       -       -       -         Very low/low       74       23.8%         Average/high       237       76.2%         Tumor grade       -       -       -         I       152       48.9%       -         II       152       48.9%       -         III       152       48.9%       -         III       126       43.7%       -         III       136       43.7%       -         III       136 <t< td=""><td>2</td><td>0.3%</td><td>4.6%</td></t<>	2	0.3%	4.6%
Country         N         %           Finland         143         46%           Portugal         76         24.4%           Israel         53         17%           Italy         39         12.5%           Education         -9 years         297         95.5%           Marital status         -9         87.5%         Single/widowed         39         12.5%           Working         -         -         87.5%         Single/widowed         39         12.5%           Working         -         -         81         26%         Nonemployed/retired         81         26%           Income         -         -         -         -         -         -         -           Very low/low         74         23.8%         - <t< td=""><td>3</td><td>_</td><td>0.3%</td></t<>	3	_	0.3%
Finland       143       46%         Portugal       76       24.4%         Israel       53       17%         Italy       39       12.5%         Education       0-9 years       14       4.5%         >9 years       297       95.5%         Marital status       8       12.5%         Married/living with a partner       272       87.5%         Single/widowed       39       12.5%         Working       230       74%         Nonemployed/retired       81       26%         Income       237       76.2%         Yery low/low       74       23.8%         Average/high       237       76.2%         Tumor grade       1       152       48.9%         II       152       48.9%       11         II       136       43.7%       11         II       136       43.7%       11         II       136       43.7%       11         III       136       43.7%       11         III       136       43.7%       12.5%         Mastectomy       80       25.7%       84.6%         No	Country	Ν	%
Portugal         76         24.4%           Israel         53         17%           Italy         39         12.5%           Education         -9         years         297         95.5%           Martied/living with a partner         272         87.5%         Single/widowed         39         12.5%           Working         -         -         Employed         39         12.5%           Working         - <t< td=""><td>Finland</td><td>143</td><td>46%</td></t<>	Finland	143	46%
Israel       53       17%         Italy       39       12.5%         Education	Portugal	76	24.4%
Italy       39       12.5%         Education $-9$ years       14       4.5%         >9 years       297       95.5%         Marital status $-79$ 87.5%         Single/widowed       39       12.5%         Working $-722$ 87.5%         Employed       230       74%         Nonemployed/retired       81       26%         Income $-74\%$ 23.8%         Average/high       237       76.2%         Tumor grade $-71\%$ 11         I       53       17%         II       152       48.9%         III       152       48.9%         III       152       48.9%         III       136       43.7%         III       28       9%         Operation $$	Israel	53	17%
Education       0-9 years       14       4.5%         >9 years       297       95.5%         Marital status       9       12.5%         Married/living with a partner       272       87.5%         Single/widowed       39       12.5%         Working       1       26%         Employed       230       74%         Nonemployed/retired       81       26%         Income       237       76.2%         Very low/low       74       23.8%         Average/high       237       76.2%         Tumor grade       1       152       48.9%         II       152       48.9%       111         Stage       1       147       47.3%         II       147       47.3%       111         Stage       1       147       47.3%         III       136       43.7%       111         III       136       43.7%       111         ILumpectomy       231       74.3%       74.3%         Mastectomy       80       25.7%       25.7%         Radiotherapy       1       147       43.3%         Yes       263       84.6	Italy	39	12.5%
0-9 years       14       4.5%         >9 years       297       95.5%         Marital status       39       12.5%         Married/living with a partner       272       87.5%         Single/widowed       39       12.5%         Working       230       74%         Employed       230       74%         Nonemployed/retired       81       26%         Income       237       76.2%         Tumor grade       1       53       17%         I       53       17%       11         II       152       48.9%       111         III       106       34.1%       Stage       9%         Operation       28       9%       9%       Operation       21       74.3%         III       136       43.7%       11       28       9%       00       25.7%         Radiotherapy       231       74.3%       74.3%       11       136       43.7%       11         III       136       43.7%       11       136       43.7%       11       143       45.3%         Mastectomy       80       25.7%       84       20.6%       141 <t< td=""><td>Education</td><td></td><td></td></t<>	Education		
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	0-9 years	14	4.5%
Marriel status       Married/living with a partner       272 $87.5\%$ Single/widowed       39 $12.5\%$ Working       230 $74\%$ Employed       230 $74\%$ Nonemployed/retired $81$ $26\%$ Income       237 $76.2\%$ Very low/low $74$ $23.8\%$ Average/high $237$ $76.2\%$ Tumor grade       I       152 $48.9\%$ II       152 $48.9\%$ III         Stage       I       147 $47.3\%$ II       136 $43.7\%$ III         Lumpectomy       231 $74.3\%$ Mastectomy $80$ $25.7\%$ Radiotherapy       Yes $247$ $79.4\%$ No       64 $20\%$ $66\%$ Endocrine treatment       Yes $263$ $84.6\%$ No       48 $15.4\%$ $75.4\%$ No       141 $45.3\%$ $75.4\%$ No       254 $81.7\%$ $75.4\%$ No       254 $81.7\%$	>9 years	297	95.5%
Married/living with a partner         272         87.5%           Single/widowed         39         12.5%           Working         230         74%           Employed         230         74%           Nonemployed/retired         81         26%           Income         237         76.2%           Very low/low         74         23.8%           Average/high         237         76.2%           Tumor grade         1         53         17%           II         152         48.9%         111           106         34.1%         Stage         1           I         147         47.3%         11           136         43.7%         111         136         43.7%           III         136         43.7%         11         136         43.7%           III         28         9%         00         25.7%         Radiotherapy         231         74.3%           Mastectomy         80         25.7%         Radiotherapy         247         79.4%           No         64         20.6%         20.6%         20.6%         20.6%           Endocrine treatment         Yes         254	Marital status		
Single/widowed3912.5%WorkingEmployed230 $74\%$ Nonemployed/retired8126%Income237 $76.2\%$ Very low/low $74$ 23.8%Average/high237 $76.2\%$ Tumor gradeI53 $17\%$ I15248.9%II10634.1%StageI147 $47.3\%$ II13643.7%III289%OperationIILumpectomy231 $74.3\%$ Mastectomy8025.7%RadiotherapyIIYes24779.4%No6420.6%Endocrine treatmentIYes26384.6%No4815.4%ChemotherapyIIYes5718.3%Anti-HER2 treatmentIYes5718.3%No2247%No22773%Psychological supportIYes3611.6%No27588.4%	Married/living with a partner	272	87.5%
Working       Employed       230 $74\%$ Nonemployed/retired       81       26%         Income       237 $76.2\%$ Very low/low $74$ $23.8\%$ Average/high       237 $76.2\%$ Tumor grade       1 $53$ $17\%$ I       53 $17\%$ II         II       152 $48.9\%$ III       106 $34.1\%$ Stage       1 $147$ $47.3\%$ II       136 $43.7\%$ III         Lumpectomy       231 $74.3\%$ Mastectomy       80 $25.7\%$ Radiotherapy       247 $79.4\%$ No       64 $20.6\%$ Endocrine treatment       Yes $263$ $84.6\%$ No       48 $15.4\%$ No         Chemotherapy       Yes $770$ $54.7\%$ No       141 $45.3\%$ Anti-HER2 treatment         Yes       57 $18.3\%$ No         No       254 $81.\%$ $75\%$ No       227	Single/widowed	39	12.5%
Employed230 $74\%$ Nonemployed/retired81 $26\%$ Income237 $76.2\%$ Very low/low $74$ $23.8\%$ Average/high $237$ $76.2\%$ Tumor grade11I $53$ $17\%$ II152 $48.9\%$ III106 $34.1\%$ Stage1147I136 $43.7\%$ II136 $43.7\%$ III136 $43.7\%$ III136 $43.7\%$ III28 $9\%$ Operation231 $74.3\%$ Mastectomy80 $25.7\%$ Radiotherapy231 $74.3\%$ Yes247 $79.4\%$ No64 $20.6\%$ Endocrine treatment $Yes$ Yes263 $84.6\%$ No48 $15.4\%$ Chemotherapy $Yes$ $57$ Yes $57$ $18.3\%$ Anti-HER2 treatment $Yes$ $57$ Yes $57$ $18.3\%$ No $227$ $73\%$ Psychotropic medication $Yes$ $84$ Yes $84$ $27\%$ No $227$ $73\%$ Psychological support $Yes$ $36$ Yes $36$ $11.6\%$ No $275$ $88.4\%$	Working		
Nonemployed/retired         81         26%           Income	Employed	230	74%
Income       74       23.8%         Average/high       237       76.2%         Tumor grade       1       53       17%         II       152       48.9%       111         106       34.1%       Stage       74         I       152       48.9%       111         106       34.1%       Stage       74         I       147       47.3%       11         11       136       43.7%       111         128       9%       Operation       74.3%         IU       28       9%       Operation       231         Lumpectomy       231       74.3%       Mastectomy       80       25.7%         Radiotherapy       231       74.3%       Mastectomy       80       25.7%         Radiotherapy       247       79.4%       No       64       20.6%         Endocrine treatment       Yes       263       84.6%       No         No       48       15.4%       Chemotherapy       Yes       141       45.3%         Anti-HER2 treatment       Yes       57       18.3%       No       227       73%         Psychotropic medication       Yes<	Nonemployed/retired	81	26%
Very low/low7423.8% Average/highAverage/high23776.2%Tumor grade15317%II15248.9%11110634.1%Stage1I14747.3%11II13643.7%111III289%Operation $231$ 74.3%Mastectomy8025.7%Radiotherapy23174.3%Yes24779.4%No6420.6%Endocrine treatment $Yes$ 263Yes26384.6%No4815.4%Chemotherapy $Yes$ 170Yes5718.3%Anti-HER2 treatment $Yes$ 57Yes5718.3%No25481.7%Psychotropic medication $Yes$ 84Yes3611.6%No27588.4%	Income		
Average/high23776.2%Tumor gradeI5317%II15248.9%III10634.1%StageI14747.3%II13643.7%III13643.7%III289%OperationILumpectomy23174.3%Mastectomy8025.7%Radiotherapy8025.7%Yes24779.4%No6420.6%Endocrine treatmentYesYes26384.6%No4815.4%ChemotherapyYes57Yes17054.7%No14145.3%Anti-HER2 treatmentYesYes5718.3%No25481.7%Psychotropic medicationYesYes8427%No22773%Psychological supportYesYes3611.6%No27588.4%	Very low/low	74	23.8%
Tumor grade       I       53 $17\%$ II       152 $48.9\%$ III       106 $34.1\%$ Stage       1       147 $47.3\%$ I       147 $47.3\%$ 11         II       136 $43.7\%$ 11         III       28 $9\%$ Operation       231 $74.3\%$ Mastectomy       231 $74.3\%$ Mastectomy       80 $25.7\%$ Radiotherapy       247 $79.4\%$ No       64 $20.6\%$ Endocrine treatment       Yes       263 $84.6\%$ No         No       64 $20.6\%$ 84 $15.4\%$ Chemotherapy       Yes $170$ $54.7\%$ No         Anti-HER2 treatment       Yes $57$ $18.3\%$ No       254 $81.7\%$ Psychotropic medication         Yes $84$ $27\%$ No $227$ $73\%$ Psychological support       Yes $36$ $11.6\%$ No $275$ $88.4\%$	Average/high	237	76.2%
I53 $17\%$ II152 $48.9\%$ III106 $34.1\%$ Stage1147 $47.3\%$ I136 $43.7\%$ II136 $43.7\%$ III28 $9\%$ Operation231 $74.3\%$ Lumpectomy231 $74.3\%$ Mastectomy80 $25.7\%$ Radiotherapy $Yes$ $247$ Yes247 $79.4\%$ No64 $20.6\%$ Endocrine treatment $Yes$ Yes263 $84.6\%$ No48 $15.4\%$ Chemotherapy $Yes$ $170$ Yes $57$ $18.3\%$ Anti-HER2 treatment $Yes$ $57$ Yes $57$ $18.3\%$ No $254$ $81.7\%$ Psychotropic medication $Yes$ $84$ Yes $84$ $27\%$ No $227$ $73\%$ Psychological support $Yes$ $36$ No $275$ $88.4\%$	Tumor grade		
II152 $48.9\%$ III106 $34.1\%$ Stage1147 $47.3\%$ II136 $43.7\%$ III136 $43.7\%$ III28 $9\%$ Operation231 $74.3\%$ Mastectomy80 $25.7\%$ Radiotherapy80 $25.7\%$ Ves247 $79.4\%$ No64 $20.6\%$ Endocrine treatment $Yes26384.6\%No4815.4\%Chemotherapy$	I	53	17%
III106 $34.1\%$ StageI147 $47.3\%$ II136 $43.7\%$ III136 $43.7\%$ III289%Operation231 $74.3\%$ Lumpectomy231 $74.3\%$ Mastectomy80 $25.7\%$ Radiotherapy79.4\%Yes24779.4%No6420.6%Endocrine treatment79.4\%Yes26384.6%No4815.4%Chemotherapy7054.7%Yes17054.7%No14145.3%Anti-HER2 treatment7718.3%Yes5718.3%No25481.7%Psychotropic medication7573%Yes3611.6%No27588.4%	II	152	48.9%
Stage       I       147       47.3%         II       136       43.7%         III       28       9%         Operation       231       74.3%         Lumpectomy       231       74.3%         Mastectomy       80       25.7%         Radiotherapy       79.4%       No         Yes       247       79.4%         No       64       20.6%         Endocrine treatment       7       14%         Yes       263       84.6%         No       48       15.4%         Chemotherapy       7       79.4%         Yes       263       84.6%         No       48       15.4%         Chemotherapy       7       79.4%         Yes       170       54.7%         No       141       45.3%         Antti-HER2 treatment       7       18.3%         Yes       57       18.3%         No       254       81.7%         Psychotropic medication       7       73%         Yes       84       27%         No       227       73%         Psychological support       7       75 <td>III</td> <td>106</td> <td>34.1%</td>	III	106	34.1%
I       147       47.3%         II       136       43.7%         III       28       9%         Operation       231       74.3%         Lumpectomy       231       74.3%         Mastectomy       80       25.7%         Radiotherapy       80       25.7%         Yes       247       79.4%         No       64       20.6%         Endocrine treatment       7         Yes       263       84.6%         No       48       15.4%         Chemotherapy       7       79.4%         Yes       263       84.6%         No       48       15.4%         Chemotherapy       7       79.4%         Yes       170       54.7%         No       141       45.3%         Antti-HER2 treatment       7       18.3%         Yes       57       18.3%         No       254       81.7%         Psychotropic medication       7       73%         Yes       84       27%         No       227       73%         Psychological support       7       58.4%         Yes <td>Stage</td> <td></td> <td></td>	Stage		
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	Ĭ	147	47.3%
III         28         9%           Operation	II	136	43.7%
$\begin{array}{c c c c c c c } Operation & & & & & & & & & & & & & & & & & & &$	III	28	9%
Lumpectomy         231         74.3%           Mastectomy         80         25.7%           Radiotherapy         80         25.7%           Radiotherapy         9         25.7%           Yes         247         79.4%           No         64         20.6%           Endocrine treatment         7         79.4%           Yes         247         79.4%           No         64         20.6%           Endocrine treatment         7         78.4%           Yes         263         84.6%           No         48         15.4%           Chemotherapy         7         78.3%           Yes         170         54.7%           No         141         45.3%           Anti-HER2 treatment         7         18.3%           Yes         57         18.3%           No         254         81.7%           Psychotropic medication         7         73%           Yes         84         27%           No         227         73%           Psychological support         7         16%           Yes         36         11.6%	Operation		
Mastectomy         80         25.7%           Radiotherapy	Lumpectomy	231	74.3%
Radiotherapy         Yes       247       79.4%         No       64       20.6%         Endocrine treatment           Yes       263       84.6%         No       48       15.4%         Chemotherapy           Yes       170       54.7%         No       141       45.3%         Anti-HER2 treatment           Yes       57       18.3%         No       254       81.7%         Psychotropic medication           Yes       84       27%         No       227       73%         Psychological support           Yes       36       11.6%         No       275       88.4%	Mastectomy	80	25.7%
Yes       247       79.4%         No       64       20.6%         Endocrine treatment       263       84.6%         No       48       15.4%         Chemotherapy       2       2         Yes       170       54.7%         No       141       45.3%         Anti-HER2 treatment       254       81.7%         Yes       57       18.3%         No       254       81.7%         Psychotropic medication       227       73%         Psychological support       227       73%         Psychological support       36       11.6%         No       275       88.4%	Radiotherapy		
No         64         20.6%           Endocrine treatment         263         84.6%           No         48         15.4%           Chemotherapy         48         15.4%           Chemotherapy         48         15.4%           No         48         15.4%           Chemotherapy         48         15.4%           Chemotherapy         48         15.4%           Yes         170         54.7%           No         141         45.3%           Anti-HER2 treatment         78           Yes         57         18.3%           No         254         81.7%           Psychotropic medication         227         73%           Yes         84         27%           No         227         73%           Psychological support         7         73%           Yes         36         11.6%           No         275         88.4%	Yes	247	79.4%
Endocrine treatment         Yes       263 $84.6\%$ No       48 $15.4\%$ Chemotherapy $Ves$ $170$ $54.7\%$ No       141 $45.3\%$ Anti-HER2 treatment $Ves$ $57$ $18.3\%$ No       254 $81.7\%$ Psychotropic medication $Ves$ $84$ $27\%$ No       227 $73\%$ Psychological support $Ves$ $36$ $11.6\%$ No       275 $88.4\%$	No	64	20.6%
Yes       263       84.6%         No       48       15.4%         Chemotherapy       48       15.4%         Yes       170       54.7%         No       141       45.3%         Anti-HER2 treatment       7       18.3%         Yes       57       18.3%         No       254       81.7%         Psychotropic medication       7         Yes       84       27%         No       227       73%         Psychological support       7       73%         Yes       36       11.6%         No       275       88.4%	Endocrine treatment		
No         48         15.4%           Chemotherapy             Yes         170         54.7%           No         141         45.3%           Anti-HER2 treatment             Yes         57         18.3%           No         254         81.7%           Psychotropic medication             Yes         84         27%           No         227         73%           Psychological support             Yes         36         11.6%           No         275         88.4%	Yes	263	84.6%
Chemotherapy         Yes         170         54.7%           No         141         45.3%           Anti-HER2 treatment         7         18.3%           Yes         57         18.3%           No         254         81.7%           Psychotropic medication         7         73%           Yes         84         27%           No         227         73%           Psychological support         7         7           Yes         36         11.6%           No         275         88.4%	No	48	15.4%
Yes       170       54.7%         No       141       45.3%         Anti-HER2 treatment	Chemotherapy		
No         141         45.3%           Anti-HER2 treatment	Yes	170	54.7%
Anti-HER2 treatment           Yes         57         18.3%           No         254         81.7%           Psychotropic medication             Yes         84         27%           No         227         73%           Psychological support             Yes         36         11.6%           No         275         88.4%	No	141	45.3%
Yes         57         18.3%           No         254         81.7%           Psychotropic medication             Yes         84         27%           No         227         73%           Psychological support             Yes         36         11.6%           No         275         88.4%	Anti-HER2 treatment		
No         254         81.7%           Psychotropic medication              Yes         84         27%            No         227         73%            Psychological support              Yes         36         11.6%            No         275	Yes	57	18.3%
Psychotropic medicationYes84No227Psychological supportYes36No27588.4%	No	254	81.7%
Yes         84         27%           No         227         73%           Psychological support         73%         73%           Yes         36         11.6%           No         275         88.4%	Psychotropic medication		
No22773%Psychological support78%Yes36No27588.4%	Yes	84	27%
Psychological supportYes36No27588.4%	No	227	73%
Yes         36         11.6%           No         275         88.4%	Psychological support		
No 275 88.4%	Yes	36	11.6%
	No	275	88.4%

BMI = body mass index, ECOG = performance status, M12 = after twelve months from the start.

3.2. Level of Exercise at Baseline and M12 and Health-Related Outcomes. After controlling for sociodemographic (i.e., age, country of origin, education, income, marital status, and employment) and medical factors (i.e., tumor stage and grade, type of treatment, receiving psychotropic treatment or psychological support, and BMI), the level of exercise at baseline was unrelated to any of the outcomes studied, namely psychological well-being, quality of life, side effects, and arm and breast symptoms (Wilks  $\Lambda = 0.98$ , *F*(12, 548) =0.96, p > 0.05, partial  $\eta^2 < 0.01$ ). However, the level of exercise at M12 was related to several of the outcomes (Wilks  $\Lambda = 0.89$ , F(12, 548) = 2.79, p < 0.001, partial  $\eta^2 = 0.06$ ; see also Table 3). The effects of the level of exercise at M12 remained statistically significant even after controlling for baseline well-being and quality of life indices (Wilks  $\Lambda = 0.90, F(12, 536) = 2.45, p < 0.01, partial \eta^2 = 0.05).$  Specifically, compared to active participants, inactive participants reported more symptoms of anxiety (F(2, 273) = 3.85, p < 0.05, partial  $\eta^2 = 0.03$ ) and depression (*F*(2, 273) = 9.49, p < 0.001, partial  $\eta^2 = 0.07$ ), lower global quality of life (F(2, (273) = 7.31, p < 0.001, partial  $\eta^2 = 0.05$ ) and more side effects  $(F(2, 273) = 4.57, p < 0.05, partial \eta^2 = 0.03)$ . According to the pairwise comparisons, no statistically significant difference existed between fairly active and active participants (see also Table 3). Regarding arm and breast symptoms, no statistically significant differences were found (Fs(2, 273) < 0.35, p > 0.05, partial  $\eta^2 s < 0.01$ ).

The change in the level of exercise from baseline to M12 was also related to several of the outcomes at M12 (Wilks  $\Lambda = 0.91$ , F(6, 275) = 4.41, p < 0.001, partial  $\eta^2 = 0.09$ ; see also Table 4). These effects remained significant even after controlling for baseline well-being and quality of life indices (Wilks  $\Lambda = 0.90$ , F(6, 269) = 4.99, p < 0.001, partial  $\eta^2 = 0.10$ ). Specifically, those who remained inactive or decreased their level of exercise reported more symptoms of anxiety (F(1, 274) = 7.32, p < 0.001, partial  $\eta^2 = 0.03$ ) and depression (F(1, 274) = 25.30, p < 0.001, partial  $\eta^2 = 0.09$ ), lower global quality of life (F(1, 274) = 13.92, p < 0.001, partial  $\eta^2 = 0.05$ ) as well as more side effects (F(1, 274) = 4.95, p < 0.05, partial  $\eta^2 = .02$ ; see also Table 4). There were no significant differences regarding arm and breast symptoms (Fs(1, 274) < 0.45, p > 0.05, partial,  $\eta^2 s < 0.01$ ).

#### 4. Discussion

Our findings showed that women with early breast cancer were more likely to maintain or increase their level of exercise than to stay inactive or decrease their level of exercise over one year from the start of oncological treatments (64% vs. 36%;  $\chi^2$  (4) = 69.97, p < 0.001). This is in line with findings of the largest prospective exercise intervention study on breast cancer survivors BREX, whereby physical activity increased both in patients randomized to exercise intervention and control groups during the early rehabilitation period [26]. However, other evidence suggests that women with early breast cancer significantly decrease their physical activity and exercise levels from one-year prediagnosis to one-year postdiagnosis when types of sports and household activity were assessed with an interview [27]. It is important to consider that the BOUNCE study period overlapped with the beginning of the COVID-19 pandemic era which could have had an impact on the results. According to a recent review, however, physical activity levels decreased, and

#### The Breast Journal

Variable		Inactive $(n = 80)$	Fairly active $(n = 92)$	Active ( <i>n</i> = 139)
Age, years		M = 53.99  (SD = 7.39)	M = 55.79  (SD = 7.91)	M = 55.94  (SD = 8.33)
8., /	<25	29 (20.6%)	42 (29.8%)	70 (49.6%)
BMI, kg/m2	>25	51 (30%)	50 (29.4%)	69 (40.6%)
Country				
Finland		19 (13.3%)	46 (32.2%)	78 (54.5%)
Portugal		24 (31.6%)	21 (27.6%)	31 (40.8%)
Israel		20 (37.7%)	15 (28.3%)	18 (34%)
Italy		17 (43.6%)	10 (25.6%)	12 (30.8%)
Education				
0-9 years		9 (64.3%)	2 (14.3%)	3 (21.4%)
>9 years		71 (23.7%)	90 (30.4%)	136 (45.9%)
Marital status				
Married/living w	ith a			
partner		70 (25.7%)	75 (27.6%)	127 (46.7%)
Single/widowed		10 (25.6%)	17 (43.6%)	12 (30.8%)
Working		(,		(,
Employed		61 (26.5%)	66 (28.7%)	103 (44.8%)
Nonemployed/ret	tired	19 (23.5%)	26 (32.1%)	36 (44 4%)
Income	liicu	19 (20.070)	20 (02.170)	30 (11.170)
Very low/low		27 (36 5%)	19 (25 7%)	28 (37.8%)
Average/high		51 (21 5%)	73(30.8%)	113(47.7%)
Tumor grade		51 (21.570)	75 (50.670)	115 (17.770)
I I I I I I I I I I I I I I I I I I I		9 (17%)	17 (32.1%)	27 (50.9%)
I		39 (25 7%)	17 (32.176) 12 (27.6%)	27(30.976) 71(46.7%)
		32(30.2%)	$\frac{42}{33} (\frac{27.0}{0})$	(40.770)
Stage		52 (50.270)	35 (31.170)	41 (38.770)
I		30 (20 4%)	41 (27.9%)	76 (51 70%)
I II & III		50 (20.4%)	(27.570)	63 (38 40%)
Operation		50 (50.5%)	51 (51.170)	05 (58.4%)
Lumportomy		EE (22.90/)	72 (21 20/)	104 (45%)
Mastactomy		33(23.6%)	72 (31.2%) 20 (25%)	104(43%)
Dadiathanany		23 (31.3%)	20 (23%)	33 (43.8%)
Nauloulerapy		F9 (22 F0/)	79(21.60/)	111 (44.00/)
1 es		30(23.3%)	70 (51.0%) 14 (21.0%)	111 (44.9%)
Endocrino trootmor	.+	22 (34.470)	14 (21.970)	28 (43.8%)
Voo	11	63 (240/)	76 (28.0%)	124(4710)
No		17(254%)	16(23.3%)	124(47.1%) 15(21.2%)
Chamatharany		17 (33,4%)	10 (33.3%)	15 (31.3%)
Voo		EQ (20 4%)	E1 (200/)	60(40.6%)
i es		50(29.4%)	51(50%)	69(40.6%)
INU Aut: LIED2 to start		50 (21.5%)	41 (29.1%)	70 (49.6%)
Anti-HER2 treatme	ent	11 (10 20/)	10 (22 20/)	27 (47 49()
Y es		(19.3%)	19(33.3%)	27(47.4%)
NO Develo et a constructione di constructione		69 (27.2%)	73 (28.7%)	112 (44.1%)
rsycnotropic medic	auon	21 (250/)		20 (45 20/)
res		21 (25%)	25 (29.8%) (7 (20.5%)	38 (45.2%)
INO Contrarret: 1 1	and and any set	59 (26%)	67 (29.5%)	101 (44.5%)
Systematic psycholo	ogical support	0 (250/)	14 (20.00/)	12 (26 10/)
res		9 (25%)	14 (38.9%)	13 (36.1%)
NO		71 (25.8%)	78 (28.4%)	126 (45.8%)

TABLE 2: Exercise habits at month 12 according to sociodemographic and medical variables (N = 311).

BMI = body mass index.

sedentary behavior increased during the COVID-19 lockdown across various populations [28] while breast cancer survivors in our study managed to maintain their activity levels. Former exercise habits predict exercise behavior during cancer survivorship [29], which was also true in our study as a significant correlation was found between exercise activity at baseline and after one year (Spearman rho = 0.54, p < 0.001). Despite the participants being more likely to maintain or increase than to decrease their activity level, only 45% of them did aerobic exercise according to the given recommendations after one year. This fact emphasizes the need for patient education to promote their physical activity from the start of oncological treatment. Patient education could help breast cancer patients to prevent maladaptive lifestyle behaviors, such as weight gain or sedentariness, and lower the risk of cancer relapse or even death [30].

In the current study, the Finnish participants were physically more active than participants from Portugal,

TABLE 3: The means and standard deviations (in parenthesis) of psychological well-being and quality of life indices across participants' level of exercise at month twelve (n = 311). Only the indices with a statistically significant difference across the various levels of exercise are included in the Table.

Index	Inactive $n = 80$ (25.7%)	Fairly active $n = 92$ (29.6%)	Active <i>n</i> = 139 (44.7%)
Anxiety	0.93 (0.65)	0.65 (0.42)	0.71 (0.52)
Depression	0.80 (0.66)	0.46 (0.39)	0.41 (0.40)
Global quality of life	66.77 (22.44)	77.54 (15.61)	78.84 (16.58)
Adverse events	22.56 (17.41)	15.27 (11.61)	18.36 (13.28)

TABLE 4: The means and standard deviations (in parenthesis) of psychological well-being and quality of life indices across the change in the level of exercise from baseline to month 12 (n = 311). Only the indices with a statistically significant difference across the changes in levels of exercise are included in the Table.

Index	Inactivity or decreased exercise $n = 112$ (36%)	Same or increased exercise $n = 199$ (64%)
Anxiety	0.87 (0.05)	0.68 (0.49)
Depression	0.71 (0.60)	0.42 (0.40)
Global quality of life	69.64 (21.13)	78.56 (16.31)
Adverse events	20.92 (16.04)	17.18 (12.96)

Israel, and Italy. This is in line with the statistics published by the European Commission in 2017, which reported that the highest proportions of people in the EU who spent at least 150 minutes per week exercising lived in Finland (54.1%) (https://ec.europa.eu/eurostat/web/products-eurostat-

news/-/DDN-20170302-1). Treatment type had no significant impact on exercise activity one year after the beginning of treatment. This lack of significance pertains to the relation between the most acute adverse events and chemotherapy or radiotherapy, which at one year have already been completed and the adverse events have eased. However, stage I patients were more active after one year than stage II and III participants. The exercise habits of study participants with more advanced stages of cancer may be affected by other factors.

Inactivity at twelve months was significantly related to several outcomes, namely to more symptoms of anxiety and depression, lower global quality of life, and more side effects. According to the available literature, exercise intervention has positive effects on several of these outcomes [31]. The positive effects of exercise mainly apply to exercising according to the recommendations of at least 150 minutes of aerobic exercise per week divided into 2-3 times [31]. Our study suggests that also exercising for 30-150 minutes per week, or increasing the amount of exercise may also have positive effects on the quality of life and mental health. The effect size of the impact of the exercise level (inactive, 30-149 minutes, 150 minutes, or more) on the outcomes after one year was medium to small. However, the effect size of the change in exercise level was medium to high (especially regarding depressive symptoms), indicating that a stable level of moderate or high exercise or an increased level of exercise activity is significantly related to better well-being. Thus, motivating patients to exercise according to general recommendations is also pertinent due to other demonstrated health benefits [20]. Accordingly, people are able to transfer skills (e.g., a person-centered perspective) from sports to other life domains, such as oncological health management. The positive attitude and behaviors learned

during sports activities may be transferred to other life contexts, helping patients in coping with mixed feelings, such as uncertainty and fear of recurrence [32].

The strength of the present study is that its participants represent a typical breast cancer population receiving various breast cancer treatments while coming from different cultural backgrounds. In the context of the BOUNCE project, extensive background material was available from a breast cancer cohort who received standard treatment, without any additional exercise intervention that could lead to the selection of more active patients for the study [26]. The literature about the physical activity of breast cancer patients concerns mainly randomized trials with some type of exercise intervention [9, 10, 12-15, 33], which can also affect patients' activity in the control group [26]. One limitation of our study is that measuring physical activity was based on participants' self-reports, without any objective digital activity measurements. Another limitation is the suboptimal sample size with a large number of drop-outs and thus a possibility of a selection bias. The study was prospective, yet correlational; therefore, no causal effects can be inferred.

## 5. Conclusions

Exercise after diagnosis of breast cancer was associated with a better quality of life, less depression, and fewer adverse events of adjuvant therapy. However, one year after beginning adjuvant therapy, less than half (45%) of the women diagnosed with breast cancer exercised according to current guidelines. Promoting motivation for physical activity among breast cancer patients from the time of diagnosis throughout the treatment phase and the first-year postdiagnosis is vital for improving their mental health and quality of life.

## **Data Availability**

The data that support the findings of this study are available upon request from the corresponding author PPS. The data are not publicly available due to restrictions e.g., they are containing information that could compromise the privacy of research participants.

## **Ethical Approval**

This study involves human participants and the experiments comply with the current laws of the countries in which they were performed.

#### Consent

The patients received oral and written information and written informed consent was obtained from all patients.

## Disclosure

AJO-M was the national coordinator for Portugal of a noninterventional study (EDMS-ERI-143085581, 4.0) to characterize a Treatment-Resistant Depression Cohort in Europe, sponsored by Janssen-Cilag, Ltd (2019–2020), is the recipient of a grant from Schuhfried GmBH for norming and validation of cognitive tests, and is the national coordinator for Portugal of trials of psilocybin therapy for treatmentresistant depression, sponsored by Compass Pathways, Ltd (EudraCT number 2017-003288-36 and 2020-001348-25), and of esketamine for treatment-resistant depression, sponsored by Janssen-Cilag, Ltd (EudraCT NUMBER: 2019-002992-33).

## **Conflicts of Interest**

The authors declare that they have no conflicts of interest.

#### Acknowledgments

This project has received funding from the European Union's Horizon 2020 Research and Innovation Programme under grant agreement No 777167. The authors thank the trial nurse Satu Karjalainen for her assistance and all the patients who participated in this study.

#### References

- N. Harbeck and M. Gnant, "Breast cancer," *The Lancet*, vol. 389, no. 10074, pp. 1134–1150, 2017.
- [2] C. Pizot, M. Boniol, P. Mullie et al., "Physical activity, hormone replacement therapy and breast cancer risk: a metaanalysis of prospective studies," *European Journal of Cancer*, vol. 52, pp. 138–154, 2016.
- [3] A. Johnsson, P. Broberg, U. Krüger, A. Johnsson, A. B. Tornberg, and H. Olsson, "Physical activity and survival following breast cancer," *European Journal of Cancer Care*, vol. 28, no. 4, Article ID e13037, 2019.
- [4] I. M. Lahart, G. S. Metsios, A. M. Nevill, and A. R. Carmichael, "Physical activity, risk of death and recurrence in breast cancer survivors: a systematic review and meta-analysis of epidemiological studies," *Acta Oncologica*, vol. 54, no. 5, pp. 635–654, 2015.

7

- [5] L. Maumy, E. Salakos, G. Rocher et al., "Physical activity after breast cancer diagnosis and survival: a systematic review," *Bulletin du Cancer*, vol. 107, no. 10, pp. 1042–1055, 2020.
- [6] D. Schmid and M. F. Leitzmann, "Association between physical activity and mortality among breast cancer and colorectal cancer survivors: a systematic review and metaanalysis," *Annals of Oncology*, vol. 25, no. 7, pp. 1293–1311, 2014.
- [7] M. E. Spei, E. Samoli, F. Bravi, C. La Vecchia, C. Bamia, and V. Benetou, "Physical activity in breast cancer survivors: a systematic review and meta-analysis on overall and breast cancer survival," *The Breast*, vol. 44, pp. 144–152, 2019.
- [8] C. M. Dieli-Conwright, K. S. Courneya, W. Demark-Wahnefried et al., "Aerobic and resistance exercise improves physical fitness, bone health, and quality of life in overweight and obese breast cancer survivors: a randomized controlled trial," *Breast Cancer Research*, vol. 20, no. 1, p. 124, 2018.
- [9] S. F. A. Duijts, M. M. Faber, H. S. A. Oldenburg, M. van Beurden, and N. K. Aaronson, "Effectiveness of behavioral techniques and physical exercise on psychosocial functioning and health-related quality of life in breast cancer patients and survivors--a meta-analysis," *Psycho-Oncology*, vol. 20, no. 2, pp. 115–126, 2011.
- [10] R. A. Ferrer, T. B. Huedo-Medina, B. T. Johnson, S. Ryan, and L. S. Pescatello, "Exercise interventions for cancer survivors: a meta-analysis of quality of life outcomes," *Annals of Behavioral Medicine*, vol. 41, no. 1, pp. 32–47, 2011.
- [11] J. T. Fuller, M. C. Hartland, L. T. Maloney, and K. Davison, "Therapeutic effects of aerobic and resistance exercises for cancer survivors: a systematic review of meta-analyses of clinical trials," *British Journal of Sports Medicine*, vol. 52, no. 20, p. 1311, 2018.
- [12] A. C. Furmaniak, M. Menig, and M. H. Markes, "Exercise for women receiving adjuvant therapy for breast cancer," *Cochrane Database of Systematic Reviews*, vol. 9, Article ID Cd005001, 2016.
- [13] I. M. Lahart, G. S. Metsios, A. M. Nevill, and A. R. Carmichael, "Physical activity for women with breast cancer after adjuvant therapy," *Cochrane Database of Systematic Reviews*, vol. 1, Article ID Cd011292, 2018.
- [14] A. Lipsett, S. Barrett, F. Haruna, K. Mustian, and A. O'Donovan, "The impact of exercise during adjuvant radiotherapy for breast cancer on fatigue and quality of life: a systematic review and meta-analysis," *The Breast*, vol. 32, pp. 144–155, 2017.
- [15] X. Zhang, Y. Li, and D. Liu, "Effects of exercise on the quality of life in breast cancer patients: a systematic review of randomized controlled trials," *Supportive Care in Cancer*, vol. 27, no. 1, pp. 9–21, 2019.
- [16] H. Penttinen, M. Utriainen, P. L. Kellokumpu-Lehtinen et al., "Effectiveness of a 12-month exercise intervention on physical activity and quality of life of breast cancer survivors; five-year results of the BREX-study," *In Vivo*, vol. 33, no. 3, pp. 881–888, 2019.
- [17] M. E. Schmidt, J. Wiskemann, P. Armbrust, A. Schneeweiss, C. M. Ulrich, and K. Steindorf, "Effects of resistance exercise on fatigue and quality of life in breast cancer patients undergoing adjuvant chemotherapy: a randomized controlled trial," *International Journal of Cancer*, vol. 137, no. 2, pp. 471–480, 2015.
- [18] J. C. Brown, T. B. Huedo-Medina, L. S. Pescatello et al., "The efficacy of exercise in reducing depressive symptoms among

cancer survivors: a meta-analysis," *PLoS One*, vol. 7, no. 1, Article ID e30955, 2012.

- [19] K. H. Schmitz, K. S. Courneya, C. Matthews et al., "American College of Sports Medicine roundtable on exercise guidelines for cancer survivors," *Medicine & Science in Sports & Exercise*, vol. 42, no. 7, pp. 1409–1426, 2010.
- [20] Physical Activities Guidelines Advisory Committee, Physical Activity Guidelines Advisory Committee Report, US Department of Health and Human Services, Washington, DC, USA, 2008.
- [21] F. C. Bull, S. S. Al-Ansari, S. Biddle et al., "World Health Organization 2020 guidelines on physical activity and sedentary behaviour," *British Journal of Sports Medicine*, vol. 54, no. 24, pp. 1451–1462, 2020.
- [22] C. Cao, C. M. Friedenreich, and L. Yang, "Association of daily sitting time and leisure-time physical activity with survival among US cancer survivors," *JAMA Oncology*, vol. 8, no. 3, p. 395, 2022.
- [23] N. K. Aaronson, S. Ahmedzai, B. Bergman et al., "The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology," *JNCI Journal of the National Cancer Institute*, vol. 85, no. 5, pp. 365–376, 1993.
- [24] M. A. Sprangers, M. Groenvold, J. I. Arraras et al., "The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: first results from a three-country field study," *Journal of Clinical Oncology*, vol. 14, no. 10, pp. 2756–2768, 1996.
- [25] A. S. Zigmond and R. P. Snaith, "The hospital anxiety and depression scale," *Acta Psychiatrica Scandinavica*, vol. 67, no. 6, pp. 361–370, 1983.
- [26] T. Saarto, H. M. Penttinen, H. Sievänen et al., "Effectiveness of a 12-month exercise program on physical performance and quality of life of breast cancer survivors," *Anticancer Research*, vol. 32, no. 9, pp. 3875–3884, 2012.
- [27] M. L. Irwin, D. Crumley, A. McTiernan et al., "Physical activity levels before and after a diagnosis of breast carcinoma: the Health, Eating, Activity, and Lifestyle (HEAL) study," *Cancer*, vol. 97, no. 7, pp. 1746–1757, 2003.
- [28] S. Stockwell, M. Trott, M. Tully et al., "Changes in physical activity and sedentary behaviours from before to during the COVID-19 pandemic lockdown: a systematic review," *BMJ Open Sport Exerc Med*, vol. 7, no. 1, Article ID e000960, 2021.
- [29] K. S. Courneya, C. M. Friedenreich, R. A. Sela, H. A. Quinney, and R. E. Rhodes, "Correlates of adherence and contamination in a randomized controlled trial of exercise in cancer survivors: an application of the theory of planned behavior and the five factor model of personality," *Annals of Behavioral Medicine*, vol. 24, no. 4, pp. 257–268, 2002.
- [30] P. Gnagnarella, D. Dragà, F. Baggi et al., "Promoting weight loss through diet and exercise in overweight or obese breast cancer survivors (InForma): study protocol for a randomized controlled trial," *Trials*, vol. 17, no. 1, p. 363, 2016.
- [31] R. Ramírez-Vélez, F. Zambom-Ferraresi, A. García-Hermoso, J. Kievisiene, A. Rauckiene-Michealsson, and C. Agostinis-Sobrinho, "Evidence-based exercise recommendations to improve mental wellbeing in women with breast cancer during active treatment: a systematic review and metaanalysis," *Cancers*, vol. 13, no. 2, p. 264, 2021.
- [32] V. Sebri, L. Savioni, S. Triberti, I. Durosini, K. Mazzocco, and G. Pravettoni, "Do you transfer your skills? From sports to health management in cancer patients," *Frontiers in Psychology*, vol. 11, p. 546, 2020.

[33] F. Hong, W. Ye, C. H. Kuo, Y. Zhang, Y. Qian, and M. Korivi, "Exercise intervention improves clinical outcomes, but the "time of session" is crucial for better quality of life in breast cancer survivors: a systematic review and meta-analysis," *Cancers*, vol. 11, 2019.